Sirtuin-4 (SIRT4), a therapeutic target with oncogenic and tumor-suppressive activity in cancer
- PMID: 29928130
- PMCID: PMC6001835
- DOI: 10.2147/OTT.S157724
Sirtuin-4 (SIRT4), a therapeutic target with oncogenic and tumor-suppressive activity in cancer
Abstract
Several members of the sirtuin (SIRT) family, a highly conserved family of NAD+-dependent enzymes, have been shown to play a critical role in both promoting and/or suppressing tumorigenesis. In this study, recent progress in the field concerning SIRT4 and cancer was reviewed, and the relationship between SIRT4 and tumors was investigated. Subsequently, we evaluated the role of SIRT4 with oncogenic or tumor-suppressive activity in cancer, which may provide insight in identifying the underlying mechanism of action of SIRT4 in cancer. Finally, we explored the potential of SIRT4 as a therapeutic target in cancer therapy.
Keywords: SIRT4; cancer; genetic instability; metabolism; sirtuin.
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
References
-
- Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 2000;403(6771):795–800. - PubMed
-
- Frye RA. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun. 2000;273(2):793–798. - PubMed
-
- Saunders LR, Verdin E. Cell biology. Stress response and aging. Science. 2009;323(5917):1021–1022. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
